New Delhi, May 2 (IANS) Akums Drugs and Pharmaceuticals on Thursday launched Amlodipine, Telmisartan & Metoprolol (ER) film-coated tablets, a fixed-dose combination (FDC) medication approved by the Drugs Controller General of India (DCGI) for the management of resistant hypertension with stable coronary artery disease.
Hypertension, a pervasive health challenge associated with significant mortality and long-term morbidity, is a major risk factor for vascular diseases such as cerebrovascular disease, ischemic heart disease, cardiac failure, and renal failure. Resistant hypertension is defined as blood pressure that stays high, even after taking three or more medicines.
The new tablets integrate the therapeutic benefits of three well-established medications into a single, convenient tablet, offering a comprehensive approach to blood pressure control.
“This new FDC embodies our commitment to improving patient outcomes and enhancing the quality of life for individuals battling hypertension,” said Sandeep Jain, MD, Akums Drugs and Pharmaceuticals.
Amlodipine’s work is to block voltage-dependent L-type calcium channels, which induces vasodilation and decreases vascular smooth muscle contractility, thereby lowering blood pressure.
Telmisartan selectively inhibits the angiotensin II AT1 receptor subtype, promoting blood vessel relaxation.
Metoprolol (ER), a cardio-selective beta-1-adrenergic receptor inhibitor, reduces cardiac output through negative inotropic and chronotropic effects.
“We believe that this formulation has the potential to improve the way we manage hypertension,” Jain added.
–IANS
rvt/svn
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
